Fubotv earnings beat by $0.10, revenue topped estimates
PORTAGE, Michigan - Medical technology company Stryker (NYSE:SYK), with a market capitalization of $143.34 billion, announced Thursday that its Board of Directors has declared a quarterly dividend of $0.84 per share, payable on October 31, 2025, to shareholders of record as of September 30, 2025.
The dividend represents a 5.0% increase compared to the same period last year, while remaining unchanged from the previous quarter’s payout. According to InvestingPro, Stryker has maintained dividend payments for 35 consecutive years and raised them for 15 straight years, demonstrating strong commitment to shareholder returns.
Stryker, which describes itself as a global leader in medical technologies, provides products and services in the MedSurg, Neurotechnology, and Orthopaedics sectors. The company states in its press release that it impacts more than 150 million patients annually through its operations worldwide. With a robust gross profit margin of 64.95% and revenue growth of 11.36%, InvestingPro analysis indicates the stock is currently trading above its Fair Value.
The quarterly dividend announcement comes as part of the company’s regular financial activities. Stryker has maintained its dividend payment schedule while implementing the year-over-year increase.
The dividend will be distributed to shareholders who own Stryker stock as of the September 30 record date, with payments being processed at the end of October.
In other recent news, Stryker Corporation reported impressive financial results for the second quarter of 2025, surpassing both earnings per share (EPS) and revenue forecasts. The company achieved an EPS of $3.13, exceeding the forecast of $3.07, and reported revenue of $6.02 billion, compared to the anticipated $5.94 billion. Following these strong results, Stryker raised its guidance for both revenue and earnings per share. The company also achieved record installations of its Mako surgical robots during the quarter. Truist Securities responded to these developments by raising its price target for Stryker to $415, while maintaining a Hold rating on the stock. Citizens JMP reiterated its Market Perform rating, noting that Stryker’s key business areas performed smoothly. These developments reflect a positive outlook for the company, as indicated by analysts’ actions and comments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.